Rafael Files FDA NDA for NPC Drug Despite Phase 3 Miss
RFL is trading near its 52-week low of $1.12 (1.8% above the low) on light trading volume (0.2× avg).
Summary
Rafael Holdings submitted an NDA to the FDA for remibetadex (Trappsol Cyclo) in Niemann-Pick Disease Type C, roughly a month after the Phase 3 TransportNPC study missed its primary endpoint. The filing leans on secondary data: a 71% relative slowing of disease progression in the prespecified background-therapy subgroup (p=0.046) and an 85% reduction in mortality risk in infantile-onset patients versus registry controls (p=0.044). Serious adverse events were more frequent on drug than placebo, 35.9% versus 16.7%. The FDA has 60 days to decide whether to accept the application and grant Priority Review; Orphan Drug, Fast Track and Rare Pediatric Disease designations are already in place, and approval would make the company eligible for a Priority Review Voucher — a potential source of non-dilutive cash for a company with a modest market value and a stock near its 52-week low. The binary risk is filing acceptance and eventual approval on data that failed its primary endpoint.
At the time of this announcement, RFL was trading at $1.14 on NYSE in the Life Sciences sector, with a market capitalization of approximately $62.9M. The 52-week trading range was $1.12 to $3.96. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.